Gastric Cancer
Conditions
Brief summary
The gastric barrier plays a major role in the maintanance of the distal intestinal microbiome composition. It has been shown before that the use of gastric acid suppression medication, such as proton pump inhibitors, are associated with distinctive alterations of the intestinal microbiome. Foremost, the invasion of predominantly oral bacteria, like Veillonella and Streptococcus species, were a resurring finding in previous reports. Gastric cancer treatment includes the total or subtotal resection of the stomach which can influence the gastric acid production. However, the influence by alterations in gastric milieu after this treatment on the composition of the intestinal microbiome is not well studied. Therefore, the intestinal microbiome of patients after total or subtotal gastrectomy and its influence on intestinal inflammation and gut permeability will be studied.
Interventions
None listed
Sponsors
Medical University of Graz
National Cancer Institute (NCI)
Vilnius University
Study design
Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* age 18 years and above * history of radical removal of gastric cancer (Test group and Control group 1) or PPI (Control group 3) * informed consent
Exclusion criteria
* chemotherapy or radiotherapy 12 months prior to inclusion * gastric stump cancer * usage of antibiotics, pro- pre or synbiotics, H2-blocker 1 month prior to inclusion * PPI use (except for Control group 3) 1 month prior to inclusion * history of radical removal of gastric cancer (Control group 2-3) * history of gastrointestinal tract resections (other than gastric) * recurrence of gastric cancer * current non-gastric malignancies
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Intestinal microbiome composition | 5 years after surgery | Significant differences in the beta-diversity of the intestinal microbiome between Test group and Control groups |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Fecal calprotectin | 5 years after surgery | Significant differences in intestinal inflammation measured by fecal calprotectin between Test group and Control groups |
| Fecal zonulin | 5 years after surgery | Significant differences in intestinal permeability measured by fecal zonulin between Test group and Control groups |
| Serum LPS | 5 years after surgery | Significant differences in serum LPS between Test group and Control groups |
| Serum sCD14 | 5 years after surgery | Significant differences in serum sCD14 between Test group and Control groups |
| Intestinal microbiome composition (II) | 5 years after surgery | Significant differences in the alpha-diversity of the intestinal microbiome between Test group and Control groups |
| Serum sCD163 | 5 years after surgery | Significant differences in serum sCD163 between Test group and Control groups |
| Serum sMR | 5 years after surgery | Significant differences in serum sMR between Test group and Control groups |
| Serum CRP | 5 years after surgery | Significant differences in serum CRP between Test group and Control groups |
| Serum DAO | 5 years after surgery | Significant differences in serum DAO between Test group and Control groups |
| Serum LBP | 5 years after surgery | Significant differences in serum LBP between Test group and Control groups |
Countries
Lithuania
Outcome results
None listed